RGS18

Across TCGA pan-cancer cohorts, RGS18 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RGS18 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RGS18 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RGS18 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, PDAC, and GBM are the cancer types where RGS18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.383	0.766	.021	11	view →
PDAC	OS	Median	II,III,IV	0.244	0.804	.038	3	view →
GBM	OS	Tertile	All	0.679	0.351	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RGS18–LUAD (OS)

Open the LUAD breakdown →